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Recognition of bacteria in the blood was one of the earliest
advances of the ‘bacteriological revolution’ in the 19th century.
The very existence and nature of bacteria was still challenged
at that time, and the work by the French physician C. F.
Davaine (1812–1882) stood out among other contributions. In
a series of elegant experiments, Davaine proved that anthrax
was caused by bacteria: first through direct visualization of the
bacteria in the blood of sick animals by microscopy; then by
infecting animals by injection of highly diluted blood from sick
animals; and finally by infecting animals with bacteria sedi-
mented from diluted blood by gravity, while inoculation of
clear liquid from the surface was harmless [1,2]. The term
bacteraemia (bacteriemie) was coined in 1872 by another
French physician, Edme Vulpian (1826–1887), to emphasize the
dissemination of the pathogen in the blood [1]. Bacteria and
fungi had not yet been assigned to separate kingdoms, and
thus, generically, bacteraemia also covers fungaemia. Blood-
stream infection was already an established term in the 1920s,
and was preferentially used in parturient and surgical patients,
and later in infection control. From the beginning of the 20th
century, blood cultures had become a practical diagnostic tool
at major hospitals in North America and Europe. Bacteraemia
research has since diversified to cover an ever-growing list of
aetiological agents, as well as different patient groups, clinical
settings, modes of acquisition, and, not least, the challenges of
antibiotic resistance.
The articles by Laupland [3] and Goto and Al-Hasan [4] in
this issue of the journal are important in a societal perspective,
because they provide compelling data on the overall incidence
and mortality of bacteraemia. Laupland reports on the
population-based incidence of bacteraemia, showing an inci-
dence range of 80 to approximately 190 episodes per 100 000
population per year, and a probable increase over time in the
absolute incidence values and in the percentage of nosocomial
cases. Goto and Al-Hasan [4] proceed further to evaluate the
population mortality associated with bacteraemia. Extrapolat-
ing from existing reports, they estimate at least 75 000 deaths
yearly in North America and 157 750 in Europe following
bacteraemia, based on the lowest estimates of bacteraemia
incidence and mortality. These estimates place bacteraemia
alone in the top eight causes of death in many European
countries and North America. However, these figures are
derived from studies reporting on short-term mortality
following bacteraemia, and the burden of bacteraemia is
probably broader. Leibovici reviews the long-term conse-
quences of bacteraemia among survivors, which are not
negligible [5]. These translate to increased long-term mortality
as compared with the general population, and cognitive and
functional decline following the bacteraemia episode.
The major limitations of the data that we have on the
burden of bacteraemia relate to the ability of existing systems
to capture all cases in a defined population and the definitions
of an episode of bactraemia [6]. Even with the most exhaustive
inclusion methods, some patients may be missed, simply
because the detection of microorganisms in blood depends on
a timely decision to obtain blood for culture. As Laupland
mentions, defining the population incidence mandates identi-
fication of all cases, but also exclusion of cases that do not
belong to the population examined [3]. Indeed, selection and
information bias can be seen as the ‘Scylla and Charybdis’ of
bacteraemia research. The definitions and methods of assigning
clinical significance to growth of bacteria in blood (as opposed
to contamination) are variable in existing studies. In this issue,
Kirn and Weinstein [7] provide an update on the definition of
bacteraemia and the methods used to obtain, process and
interpret blood cultures, which might help to standardize
practice and research. Finally, the attribution of polymicrobial
bacteraemia [8] and the assignment of continuous or relapsing
bacteraemia are not uniform. The temporal limits of individual
bacteraemic episodes have varied considerably among studies,
and this had a significant impact on numbers of recurrences
and thus total numbers of bacteraemias [9].
Where do we go from Here?
Despite the difficulties, epidemiological surveillance and pop-
ulation-based studies should continue to be an important
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means of evaluating trends in bacterial epidemiology and the
burden of infection. Standardization of definitions and methods
can improve the quality of the data and comparability between
studies. Surveillance systems, such as that for central-line-
associated bloodstream infections [10], should be devised for
all bloodstream infections. However, as observed by Goto and
Al-Hasan, surveillance systems might exaggerate incidence
values, owing to referral bias. Thus, efforts must be made to
include all types of hospitals in such surveillance systems. The
most appropriate sources of information on bloodstream
infections are the electronic information systems used by
clinical microbiology laboratories. Although additional clinical
data are highly desirable, surveillance and research data can be
obtained by the use of robust algorithms [11–13]. Already in
1969, Martin envisaged a national bacteraemia registry in the
USA [14]. A few countries, such as Finland, Denmark, and the
UK, have national registries [15–17]; however, these are still
rare.
As well as constituting a window on the burden of sepsis,
research based on bacteraemia has provided and will continue
to provide an important means of examining the management
of sepsis. A simple merit of bacteraemia is the possibility of
evaluating the outcome of antibiotic therapy, as the causative
agents and their susceptibility patterns are always known.
Another important merit is the simplicity of including patients
from a wide variety of clinical specialties and in diverse settings.
Studies on new antibiotics or other interventions should focus
on bacteraemia rather than on skin/soft tissue or abdominal
infections.
Better Management of Bloodstream
infections
Mortality rates following bacteraemia have not decreased in
recent years; rather, the increase in the proportion of
nosocomial cases might have resulted in an increase in the
population mortality related to bacteraemia [3,4]. To decrease
the global burden of bacteraemia, prevention and improved
management are necessary. Early appropriate antibiotic treat-
ment has repeatedly been shown to decrease mortality, but is
only achieved in approximately 70% of patients with bactera-
emia, with no significant improvement with time [18,19]. There
is a delicate balance between the knowledge that early
appropriate antibiotic treatment improves survival, but that
unnecessary antibiotic treatment will trigger antibiotic resis-
tance, and thus broad-spectrum antibiotic treatment for all is
non-sustainable. With increasing numbers of multidrug-resistant
bacteria, the latter part of this balance is receiving increasing
attention and weight. Improved sensitivity of the microbiological
methods would allow exclusion of bacterial infection and
discontinuation of antibiotics when they are not needed.
Methods for rapid detection and bacterial identification, such
as matrix-assisted laser desorption ionization time-of-flight
mass spectrometry, would allow for earlier directed antibiotic
treatment [20]. The incorporation of decision support could
improve the rates of appropriate empirical antibiotic treatment
and result in a better, explicit balance between the ecological
costs and the benefits of antibiotic treatment, leading to more
judicious antibiotic prescription [21,22]. Hopefully, a combina-
tion of these technologies will succeed in curbing the increasing
burden of sepsis and bacteraemia.
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